Avrobio

AVROBIO, Inc is a gene therapy company in Phase II clinical stage, focusing on developing ex vivo lentiviral-based gene therapies with potential therapeutic functions to treat rare diseases with a single treatment. AVROBIO's initial product pipeline includes four lentiviral-based gene therapies: AVR-RD-01 for the treatment of Fabry disease, AVR-RD-02 for Gaucher disease, AVR-RD-03 for Pompe disease, and AVR-RD-04 for cystinosis.